TABLE 2.

Combined data from study 2 comparing the assay performances of six commercial serology tests and the cPass sVNT^a

Assay	Analyte	Time after symptom onset																	Negative samples (serum collected before Nov 2019)					PPV (%)	NPV (%)	ACC (%)
		5–9 days				10–19 days				>19 days				All time points					No. of Neg samples	No. of Equ samples	No. of Pos samples	Spec (%)	CI (%)
		No. of Neg samples	No. of Pos samples	Sens (%)	CI (%)	No. of Neg samples	No. of Pos samples	Sens (%)	CI (%)	No. of Neg samples	No. of Pos samples	Sens (%)	CI (%)	No. of Neg samples	No. of Pos samples	Sens (%)	CI (%)	Total no. of samples
Abbott	IgG	0	6	100	54–100	3	9	75	43–95	0	9	100	66–100	3	24	89	71–98	27	49	0	1	98	89–100	83	99	97
Affinity	IgG	0	7	100	59–100	2	11	85	55–98	0	8	100	63–100	2	26	93	71–98	28	47	0	0	100	92–100	100	99	99
Bio-Rad	IgG	0	6	100	54–100	3	9	75	43–95	0	9	100	66–100	3	24	89	71–98	27	50	0	0	100	93–100	100	99	99
DiaSorin	IgG	4	2	33	4–78	4	8	67	35–90	0	9	100	66–100	8	19	70	71–98	27	48	1	1	96	86–100	66	97	93
Euroimmun	IgG	3	3	50	12–88	4	8	67	35–90	0	8	100	63–100	7	19	73	71–98	26	50	0	0	100	93–100	100	97	97
Roche	Total Ab	1	6	86	42–100	4	9	69	39–91	0	9	100	66–100	5	24	83	71–98	29	50	0	0	100	93–100	100	98	98
GenScript	RBD-hACE2	1	6	86	42–100	1	12	92	64–100	0	9	100	66–100	2	27	93	71–98	29	50	0	0	100	93–100	100	99	99

^aSensitivity (Sens), specificity (Spec), accuracy (ACC), positive predictive values (PPV), and negative predictive values (NPV) are shown. Pos, positive; Neg, negative; CI, 95% confidence interval; Equ, equivocal result; Ab antibody. A prevalence of 10% was used for the calculations.